Warby Parker Inc. (WRBY)
USD 23.71
(-2.39%)
USD 23.71
(-2.39%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -30.21 Million USD | 57.85% |
| 2022 | -78.03 Million USD | 34.86% |
| 2021 | -121.7 Million USD | -226.92% |
| 2020 | -37.25 Million USD | -389.85% |
| 2019 | 12.85 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 2.16 Million USD | -60.32% |
| 2024 Q1 | 5.45 Million USD | 162.13% |
| 2023 Q4 | -11.19 Million USD | -11.91% |
| 2023 Q3 | -10 Million USD | -11.86% |
| 2023 Q2 | -8.94 Million USD | -171.91% |
| 2023 Q1 | -3.29 Million USD | 84.85% |
| 2023 FY | - USD | 57.85% |
| 2022 Q3 | -15.74 Million USD | 34.95% |
| 2022 Q2 | -24.2 Million USD | 9.03% |
| 2022 Q1 | -26.6 Million USD | 32.39% |
| 2022 FY | - USD | 34.86% |
| 2022 Q4 | -21.71 Million USD | -37.91% |
| 2021 Q4 | -39.34 Million USD | 57.22% |
| 2021 FY | - USD | -226.92% |
| 2021 Q3 | -91.97 Million USD | -2393.33% |
| 2021 Q2 | -3.68 Million USD | -147.75% |
| 2021 Q1 | 7.72 Million USD | 22820.59% |
| 2020 Q4 | -34 Thousand USD | 99.91% |
| 2020 Q3 | -37.01 Million USD | -36014.15% |
| 2020 Q1 | -102.5 Thousand USD | 0.0% |
| 2020 Q2 | -102.5 Thousand USD | 0.0% |
| 2020 FY | - USD | -389.85% |
| 2019 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alcon Inc. | 2.39 Billion USD | 101.262% |
| AptarGroup, Inc. | 663.83 Million USD | 104.551% |
| Baxter International Inc. | 2.77 Billion USD | 101.088% |
| Becton, Dickinson and Company | 2.42 Billion USD | 101.246% |
| Bausch + Lomb Corporation | 586 Million USD | 105.156% |
| Haemonetics Corporation | 262.09 Million USD | 111.527% |
| Envista Holdings Corp | 171.1 Million USD | 117.658% |
| ResMed Inc. | 1.6 Billion USD | 101.888% |
| Teleflex Incorporated | 792.26 Million USD | 103.813% |
| West Pharmaceutical Services, Inc. | 847.8 Million USD | 103.564% |